J. Alonso, M. C. Angermeyer, S. Bernert, R. Bruffaerts, T. S. Brugha et al., Prevalence of mental disorders in Europe: Results from the European study of the epidemiology of mental disorders (ESEMeD) project, Acta Psychiatrica Scandinavica. Supplementum, issue.420, pp.8-20, 2004.

, Practice guideline for the assessment and treatment of patients with suicidal behaviors, American Psychiatric Association, vol.160, pp.1-60, 2003.

, Practice guideline for the treatment of patients with major depressive disorder, American Psychiatric Association, pp.1-152, 2010.

. S. Anaes.-;-g, C. Collin, T. Le-tri, A. Pariente, B. Begaud et al., Antidepressants and hepatotoxicity: A cohort study among 5 million individuals registered in the French national health insurance database, CNS Drugs, vol.32, pp.673-684, 2002.

S. A. Bliss and J. K. Warnock, Psychiatric medications: Adverse cutaneous drug reactions, Clinics in Dermatology, vol.31, pp.101-109, 2013.

C. De-bodinat, B. Guardiola-lemaitre, E. Mocaer, P. Renard, C. Munoz et al., Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development, Nature Reviews Drug Discovery, vol.9, pp.628-642, 2010.

E. Bromet, L. H. Andrade, I. Hwang, N. A. Sampson, J. Alonso et al., Cross-national epidemiology of DSM-IV major depressive episode, BMC Medicine, vol.9, p.90, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00617550

E. Chesney, G. M. Goodwin, and S. Fazel, Risks of all-cause and suicide mortality in mental disorders: A meta-review, World Psychiatry, vol.13, pp.153-160, 2014.

A. Cipriani, T. A. Furukawa, G. Salanti, A. Chaimani, L. Z. Atkinson et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis, Lancet, vol.391, pp.1357-1366, 2018.

J. R. Davidson, Major depressive disorder treatment guidelines in America and Europe, Journal of Clinical Psychiatry, vol.71, p.4, 2010.

A. J. Ferrari, A. J. Somerville, A. J. Baxter, R. Norman, S. B. Patten et al., Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature, Psychological Medicine, vol.43, pp.471-481, 2013.

B. Guardiola-lemaitre, B. C. De, P. Delagrange, M. J. Millan, C. Munoz et al., Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties, British Journal of Pharmacology, vol.171, pp.3604-3619, 2014.

W. Guy, ECDEU assessment manual for psychopharmacology. Rockville MD: US Department of Health, Education and Welfare publication ADM 76-338, 1976.

. Ispe, Guidelines for good pharmacoepidemiology practices (GPP), Pharmacoepidemiology and Drug Safety, vol.17, pp.200-208, 2008.

S. H. Kennedy and R. Emsley, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, European Neuropsychopharmacology, vol.16, issue.2, pp.93-100, 2006.

S. H. Kennedy and S. J. Rizvi, Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness, CNS Drugs, vol.24, pp.479-499, 2010.

. Servier-laboratories, Summary of product characteristics: Valdoxan, Lancet, vol.367, pp.2041-2043, 2006.

M. V. Mitkov, R. M. Trowbridge, B. N. Lockshin, and J. P. Caplan, Dermatologic side effects of psychotropic medications, Psychosomatics, vol.55, pp.1-20, 2014.

A. L. Montejo, J. F. Deakin, R. Gaillard, C. Harmer, F. Meyniel et al., Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale, Journal of Psychopharmacology, vol.29, pp.1119-1128, 2015.

A. L. Montejo, N. Prieto, A. Terleira, J. Matias, S. Alonso et al., Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale, Journal of Psychopharmacology, vol.24, pp.111-120, 2010.

S. A. Montgomery, S. H. Kennedy, G. D. Burrows, M. Lejoyeux, and I. Hindmarch, Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study, International Clinical Psychopharmacology, vol.19, pp.271-280, 2004.

A. Nischal, A. Tripathi, A. Nischal, and J. K. Trivedi, Suicide and antidepressants: What current evidence indicates, Mens Sana Monographs, vol.10, pp.33-44, 2012.

G. Perlemuter, P. Cacoub, D. Valla, D. Guyader, B. Saba et al., Characterisation of agomelatine-induced increase in liver Enzymes: Frequency and risk factors determined from a pooled analysis of 7605 treated patients, CNS Drugs, vol.30, pp.877-888, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01373303

M. Pladevall-vila, A. Pottegard, T. Schink, J. Reutfors, R. Morros et al., Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: A cohort and nested case-control study using automated health data sources, CNS Drugs, vol.33, pp.383-395, 2019.

A. Qaseem, V. Snow, T. D. Denberg, M. A. Forciea, and D. K. Owens, Using second-generation antidepressants to treat depressive disorders: A clinical practice guideline from the American college of physicians, Annals of Internal Medicine, vol.149, pp.725-733, 2008.

S. Rose, International ethical guidelines for epidemiological studies: by the Council for International Organizations of Medical Sciences (CIOMS), American Journal of Epidemiology, vol.170, issue.11, pp.1451-1452, 2009.

D. V. Sheehan, K. Harnett-sheehan, and B. A. Raj, The measurement of disability, International Clinical Psychopharmacology, vol.11, pp.89-95, 1996.

D. Taylor, A. Sparshatt, S. Varma, and O. Olofinjana, Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies, BMJ, vol.348, 1888.

C. S. Voican, E. Corruble, S. Naveau, and G. Perlemuter, Antidepressant-induced liver injury: A review for clinicians, American Journal of Psychiatry, vol.171, pp.404-415, 2014.

C. S. Voican, S. Martin, C. Verstuyft, E. Corruble, G. Perlemuter et al., Liver function test abnormalities in depressed patients treated with antidepressants: A real-world systematic observational study in psychiatric settings, PLoS One, p.155234, 2016.

A. Wade, N. Despiegel, and R. E. Heldbo, Escitalopram in the longterm treatment of major depressive disorder, American Journal of Psychiatry, vol.18, pp.83-89, 2006.

P. Gorwood, J. Benichou, and N. Moore, The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study, Hum Psychopharmacol Clin Exp, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02969124

,

. Gorwood and . Al,